Introduction
Characteristics | Total | Non-HCC | HCC |
---|---|---|---|
Tumor type | |||
Cutaneous melanoma | 7 | 7 | 0 |
Uveal melanoma | 1 | 1 | 0 |
NSCLC | 1 | 1 | 0 |
HCC recurred with pulmonary | 2 | 0 | 2 |
HCC | 9 | 0 | 9 |
Immunotherapy | |||
Nivolumab | 10 | 1 | 9 |
Pembrolizumab | 7 | 5 | 2 |
Ipilimumab | 1 | 1 | 0 |
Ipilimumab + pembrolizumab | 2 | 2 | 0 |
Liver transplant outcome | |||
Graft preservation | 13 | 6 | 7 |
Graft rejection with graft failure | 4 | 1 | 3 |
Graft rejection without graft failure/UK | 3 | 2 | 1 |
Final outcome | |||
CR | 2 | 2 | 0 |
PR | 3 | 2 | 1 |
PD | 8 | 3 | 5 |
Death from organ failure before evaluation | 4 | 1 | 3 |
UK | 3 | 1 | 2 |
Age | Sex | Transplant to malignancy/ICIs (years) | IST before ICIs | IST during ICIs | Malignancy | Treatment before initiation of ICIs | ICIs (cycles) | Outcomes (TTR) (PFS) | OR | OF | Reasons for transplantation | Cause of death | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Morales et al. [53] | 67 | M | 1/10 | Tacrolimus + MMF/mTOR inhibitor + MMF (after metastatic HCC was diagnosed) | Low-dose sirolimus (1 mg) | Melanoma/metastatic HCC | Chemotherapy (paclitaxel) + palliative radiotherapy to the hip | Ipilimumab (4) | PR(3 months) | No | – | HCC | – |
(10 monthsa) | |||||||||||||
Ranganath et al. [51] | 59 | F | 7/8 | Tacrolimus (1 mg) | Tacrolimus (< 3.1 ng/ml) | Melanoma | Adjuvant interferon + local radiation | Ipilimumab (4) | PD | No | – | Cirrhosis (due to α1-trypsin deficiency) | UK |
Pembrolizumab (2 mg/kg) (after PD) | |||||||||||||
Kuo et al. [1] | 62 | F | 5/5 | Prednisone + tacrolimus (4 mg) + MMF | Low-dose sirolimus (1 mg) + MMF (500 mg 2xpd) | MPNST like melanoma | – | Ipilimumab(4) | PR (3 months) | No | – | HCC | – |
Pembrolizumab (25) | (17 monthsa) | ||||||||||||
Schvartsman et al. [54] | 35 | M | 15/18 | Tacrolimus | Tacrolimus | Melanoma | Chemotherapy (carboplatin + paclitaxel) | Pembrolizumab (2) | CR (UK) (6 monthsa) | No | – | Biliary atresia | – |
Tio et al. [48] | 63 | F | UK | UK | Cyclosporine | Melanoma | UK | Pembrolizumab (1) | Death due to OF (3 weeks after start ICIs) | Yes | Yes | NS | OF (18 days after start ICIs) |
Dueland et al. [61] | 67 | F | 1.5/1.5 | Sirolimus + MMF | Prednisone (10 mg) | Ocular melanoma | UK | Pembrolizumab (1 mg/kg) | PD | Yes | No | Liver metastasis | PD |
Biondani et al. [55] | 54 | M | 12/13 | Tacrolimus + prednisone + MMF | Everolimus + tacrolimus+ | NSCLC | Surgery + adjuvant chemotherapy (cisplatin–vinorelbine) | Nivolumab | PD | No | – | Hepatitis C | PD |
prednisone(60–5 mg) | |||||||||||||
DeLeon et al. [50] | 54 | M | 5/UK | UK | MMF + everolimus | Melanoma | UK | Pembrolizumab (9.5 months) | CR (21 monthsa) | No | – | HCC | – |
DeLeon et al. [50] | 63 | M | 3/UK | UK | MMF + prednisone | Melanoma | UK | Pembrolizumab (1) | UK | Yes | No | HCC | – |
DeLeon et al. [50] | 56 | M | 2/UK | UK | Tacrolimus | HCC | UK | Nivolumab (6) | PD | No | – | HCC | Probably PD |
DeLeon et al. [50] | 55 | M | 7/UK | UK | Sirolimus + MMF | HCC | UK | Nivolumab (5) | PD | No | – | HCC | Probably PD |
DeLeon et al. [50] | 34 | F | 3/UK | UK | Tacrolimus | HCC | UK | Nivolumab | PD | No | – | HCC | Probably PD |
DeLeon et al. [50] | 63 | M | 1/UK | UK | Tacrolimus | HCC | UK | Nivolumab | UKb | No | – | HCC | MOF |
DeLeon et al. [50] | 68 | M | 1/UK | UK | Sirolimus | HCC | UK | Nivolumab | UKb | Yes | UK | HCC | PD |
De Toni et al. [63] | 41 | M | 1/UK | UK | Tacrolimus (1 mg) | HCC | TACE + microwave ablation | Nivolumab (15) | Dissociated response (7 months) PD hereafter | No | – | HCC | PD |
Varkaris et al. [62] | 70 | M | 6/8 | Tacrolimus | Low-dose (50%) tacrolimus | HCC | Sorafenib | Pembrolizumab | PD | No | – | HCC | PD |
Gassmann et al. [41] | 53 | F | 2/2 | Prednisone + MMF(1 to 2 g/d) + everolimus 1 mg/d | Everolimus + MMF | HCC recurred with pulmonary | Sorafenib | Nivolumab(1) | Death due to OF (2 weeks after start ICIs) | Yes | Yes | HCC | OF (2 weeks after start ICIs) |
Friend et al., [42] | 14 | M | 1/UK | UK | Tacrolimus (4 mg) | Fibrolamellar HCC | Sorafenib + gemcitabine + oxaliplatin | Nivolumab(1) | Death due to OF (5 weeks after start ICIs) | Yes | Yes | HCC | OF (5 weeks after start ICIs) |
Friend et al., [42] | 20 | M | 3/UK | UK | Sirolimus (2 mg) | Fibrolamellar HCC | Sorafenib + capecitabine monotherapy | Nivolumab (2) | Death due to OF (4 weeks after start ICIs) | Yes | Yes | HCC | OF (4 weeks after start ICIs) |
Rammohan et al. [56] | 57 | M | 4/5 | Tacrolimus + MMF + steroid | Tacrolimus + MMF + steroid + mTOR inhibitor | HCC recurred with pulmonary | Sorafenib | Pembrolizumab | Complete radiological resolution | No | – | HCC | – |